# PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Source: https://onco.cc/trials/nct06607627/  
OnCo record `nct06607627` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gefurulimab in childhood cancers, run by Alexion Pharmaceuticals, Inc., now recruiting.

## Summary

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT06607627 by Alexion Pharmaceuticals, Inc., with 12 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-15. Interventions recorded: Gefurulimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06607627
- Phase: 3
- Setting: An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)
- Sponsor: Alexion Pharmaceuticals, Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06607627: https://clinicaltrials.gov/study/NCT06607627

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06607627.json